NCT05950659招募中不适用
Prevention of Foot Ulcer Recurrence in Individuals Who Are at High-risk for Diabetic Foot Complications Using the Orpyx Sensory Insole System: a Multisite, Randomized, Controlled Trial
Johns Hopkins University1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2026年4月22日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Plantar ulcer recurrence
研究概览
简要总结
The primary aim of this study is to demonstrate the impact of the Orpyx® Sensory Insoles (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to the standard of care (SOC), as compared to SOC alone, on reducing plantar ulceration incidence in individuals who are at risk for developing diabetic foot complications.
The secondary aims of this study are to evaluate participant quality of life, participant engagement, and economic impact, including cost-effectiveness and cost-utility. The study will also use the unique data set collected (plantar pressure, temperature, step count, movement and adherence feedback) to identify foot-loading histories that either lead to or prevent the development of ulceration in the diabetic foot.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed Type 1 or 2 diabetes
- •Clinically diagnosed neuropathy via Neuropathy Monofilament Test (Appendix A)
- •Qualification as a "high-risk participant," meaning a recent history (<12 months) of a healed diabetic neuropathic ulceration on the weight-bearing surface of one or both feet (this includes the plantar distal toe surface)
- •Complete healing of any previous foot ulcers, as defined by complete re-epithelialization of that ulcer which is confirmed by two medical exams that occur at least two weeks apart (screening visit and baseline study visit)
- •Ability to walk independently (without use of wheelchair) for 30 steps. Use of a walker or cane is acceptable as long as the participant can walk for at least 30 steps.
- •Aged >18 years
- •ABI > 0.6 or TBI > 0.4 or palpable pulses or evidence of healing in the last 2 months. If ABI < 0.4, the patient's vascular lab studies (ABI, TBI, pulse volume recordings) will be reviewed by the study PI and a co-I vascular surgeon at USC.
- •Subject is willing and able to maintain the required offloading (as applicable for the location of the healed ulcer)
- •Subject is willing and able to wear the Orpyx Sensory Insoles during ambulatory activity and at home during waking hours, and for a minimum of 5 hours per day
- •Amputations, if present, are compatible with the use of insoles at physician discretion (e.g. Transmetatarsal Amputation (TMA) are acceptable)
排除标准
- •Active ulcer or presence of other open chronic wound (on foot or leg), regardless of etiology (e.g., vasculitis, neoplasms, or hematological disorders)
- •Psychiatric illness or social situations that would limit compliance with the study
- •Significant cardiopulmonary, severe imbalance, or other systemic disease limiting the participant's ability to walk at least 30 steps or to stand for an amount of time equal to or greater than five (5) minutes (self-reported)
- •Current participation in another clinical investigation of a similar medical device designed to offload or prevent diabetic foot ulcer formation; or participation in such a study within 30 days prior to study enrollment, per physician discretion
- •Current enrollment in any other remote patient pedal monitoring (RPPM) program
- •Osteomyelitis or gangrene of the lower extremity
- •Uncorrected plantar Charcot neuroarthropathy
- •Bunion which would predispose ulcer formation (clinician discretion)
- •Extreme equinus
- •At the start of V1, and prior to randomization, the subject no longer meets the entrance criteria (inclusion and exclusion)
- •Above ankle amputation
- •Amputations not compatible with the insole, per physician discretion
- •Foot deformities or amputations that require surgical intervention as the next step in standard of care, and that the study footwear and device would not adequately address (to be adjudicated by an outside review panel).
- •Brannock-measured foot size > Men's 14 (Women's 12)
- •Physician discretion
研究组 & 干预措施
Control
No Intervention
Intervention
Experimental
干预措施: Orpyx Sensory Insole System (Device)
结局指标
主要结局
Plantar ulcer recurrence
时间窗: 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Therapeutic Stockings to Prevent Foot UlcersDiabetesNCT01221194University of Texas Southwestern Medical Center381
Unknown
不适用
Insole Optimisation for Ulcer Prevention: a Feasibility TrialDiabeticNeuropathicPast UlcerationNCT01948479University of Plymouth20
Unknown
不适用
Plantar Fasciitis Foot InsolePlantar FasciitisNCT01549678Federal University of São Paulo74
Unknown
不适用
Evaluation of Carbothera in the Treatment of Foot UlcersCritical Lower Limb IschemiaCritical Limb IschemiaFoot UlcerSkin UlcerationNCT02239419University of Manitoba40
已完成
不适用
Prevention of Secondary Foot Ulcers in Patients With Diabetes Using Systematic Measuring of Skin Temperature.Foot Ulcer, DiabeticNCT01269502Oslo University Hospital41